Lates News

In the early trading on Wednesday, the stock price of Celldex Therapeutics (CLDX) plunged by 9.5% as its drug Barzolvolimab failed to improve symptoms of Eosinophilic Esophagitis (EoE) despite reaching the main endpoint in its phase II trial.